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Abstract
Background: Dengue infection can cause a wide spectrum of clinical outcomes. The severe clinical manifestations
occur sufficiently late in the disease course, during day 4–6 of illness, to allow a window of opportunity for risk
stratification. Markers of inflammation may be useful biomarkers. We investigated the value of C-reactive protein
(CRP) measured early on illness days 1–3 to predict dengue disease outcome and the difference in CRP levels
between dengue and other febrile illnesses (OFI).
Method: We performed a nested case-control study using the clinical data and samples collected from the IDAMS-
consortium multi-country study. This was a prospective multi-center observational study that enrolled almost 8000
participants presenting with a dengue-like illness to outpatient facilities in 8 countries across Asia and Latin
America. Predefined severity definitions of severe and intermediate dengue were used as the primary outcomes. A
total of 281 cases with severe/intermediate dengue were compared to 836 uncomplicated dengue patients as
controls (ratio 1:3), and also 394 patients with OFI.
Results: In patients with confirmed dengue, median (interquartile range) of CRP level within the first 3 days was
30.2 mg/L (12.4–61.2 mg/L) (uncomplicated dengue, 28.6 (10.5–58.9); severe or intermediate dengue, 34.0 (17.4–
71.8)). Higher CRP levels in the first 3 days of illness were associated with a higher risk of severe or intermediate
outcome (OR 1.17, 95% CI 1.07–1.29), especially in children. Higher CRP levels, exceeding 30 mg/L, also associated
with hospitalization (OR 1.37, 95% CI 1.14–1.64) and longer fever clearance time (HR 0.84, 95% CI 0.76–0.93),
especially in adults. CRP levels in patients with dengue were higher than patients with potential viral infection but
lower than patients with potential bacterial infection, resulting in a quadratic association between dengue
diagnosis and CRP, with levels of approximately 30 mg/L associated with the highest risk of having dengue. CRP
had a positive correlation with total white cell count and neutrophils and negative correlation with lymphocytes,
but did not correlate with liver transaminases, albumin, or platelet nadir.
Conclusions: In summary, CRP measured in the first 3 days of illness could be a useful biomarker for early dengue
risk prediction and may assist differentiating dengue from other febrile illnesses.
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Background
Dengue, caused by one of the four dengue virus sero-
types (DENV1–4), is globally the most important arbo-
viral infection, in terms of geographic spread and
number of infections [1]. An estimated 390 million in-
fections now occur annually in over 100 countries, of
which 96 million manifest as symptomatic dengue cases
[2]. The clinical phenotype can vary from a relatively
mild self-limiting febrile illness, to severe and occasion-
ally life-threatening symptoms of bleeding, organ impair-
ment, and vascular leakage leading to shock [3]. These
severe manifestations occur sufficiently late in the course
of the disease around defervescence, which occurs usu-
ally on day 4–6 following illness onset, to allow a poten-
tial window of opportunity to identify patients who may
progress.
In areas of dengue transmission, yearly seasonal epi-
demics occur and can very quickly overwhelm health fa-
cilities, with potentially thousands of patients being
reviewed daily. As the vast majority of symptomatic in-
fections will result in a benign disease course, the ability
to identify patients at high risk of progression, who are
likely to benefit from early intervention with supportive
therapy, has become the focus of intense research efforts
in recent years.
Several small studies have attempted to identify bio-
markers for dengue that will be cost-effective in
resource-limited settings [4]. Recent evidence suggests
that markers of inflammation may be useful as bio-
markers. Studies have shown higher levels of C-reactive
protein (CRP) in severe dengue versus non-severe den-
gue, with a CRP cutoff level of 30.1 mg/L (AUC, 0.938;
100% sensitivity, 76.3% specificity) [5]. In adult patients
in Indonesia on the third day of fever, CRP was higher
in those who developed plasma leakage, 10.1 (IQR 4.3–
36.5) vs. 6.3 (IQR 3.0–21.6) mg/L (p = 0.014) [6]. Other
studies using highly sensitive (hs) CRP did not find a dif-
ference between the severity grades [7]. Higher levels of
CRP have also been found in patients with dengue com-
pared to other viral illnesses [8].
A lack of harmonization between these studies has
made the results difficult to compare, with varying assay
techniques, viral serotypes, age of the participants, im-
mune status, and illness day at the time of sampling. To
provide a definitive answer as to the utility of CRP meas-
urement for diagnosis and risk prediction in dengue,
these results require validation in a large sample set in-
cluding early and dynamic sampling, and using a stan-
dardized assay.
We hypothesized that (1) dengue patients with higher
CRP levels in the early febrile phase are at higher risk of
developing severe disease and (2) dengue patients have
higher CRP levels than patients with other viral febrile
illnesses.
Methods
Study design
A nested case-control study was performed using the clin-
ical data and blood samples already collected from patients
recruited to the observational study entitled “Clinical evalu-
ation of dengue and identification of risk factors for severe
disease” (IDAMS study, NCT01550016), for which the
protocol has been published [9]. Briefly, this prospective
multi-center observational study enrolled 7428 participants
aged 5 years or more, presenting with a febrile illness con-
sistent with dengue to outpatient health facilities in 8 coun-
tries across Asia and Latin America. Patients at the
participating sites were eligible for enrollment if they met
the following criteria: fever or history of fever for less than
72 h and clinical symptoms consistent with possible den-
gue, and had no localizing features suggesting an alternative
diagnosis, e.g., pneumonia. Participants were then followed
daily until resolution of their acute illness, with a standard
schedule of blood samples obtained during the illness
course. Hospital admission and individual case manage-
ment were determined according to clinical need, with all
interventions documented in the case report forms. Subse-
quently, each participant was assigned an overall severity
grading using all available information; the system used is
described in detail in Additional file 1 and is in line with
the recent recommendation to use standardized endpoints
for severe and intermediate dengue to ensure reproducibil-
ity and comparability of research findings [10].
Study population
Samples from participants enrolled at five study sites
were selected, including Hospital for Tropical Diseases
(HTD) (Ho Chi Minh City, Vietnam), National Hospital
for Tropical Diseases (NHTD) (Hanoi, Vietnam), Angkor
Hospital for Children (Siem Reap, Cambodia), University
of Malaya Medical Centre (Kuala Lumpur, Malaysia),
and Hospital Nacional de Niños Benjamin Bloom (El
Salvador). Stored samples from patients who progressed
to severe or intermediate dengue severity were selected
as well as a comparison group of uncomplicated dengue
and other febrile illnesses (OFI). This cohort included 38
severe and 243 intermediate severity cases (combined
primary outcome of 281 cases). The 281 cases were
compared to 839 uncomplicated dengue patients as con-
trols (1:3), based on similar geographic and demograph-
ics and day of illness (DOI) making a total sample size
of 1120 dengue cases. Confirmed dengue cases were
compared to 400 patients with OFI, again from the same
locations and with the same demographics and DOI.
The study flowchart is shown in Fig. 1.
Case definitions
Dengue diagnostic criteria have been described elsewhere;
briefly, laboratory-confirmed dengue was defined by either
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a positive RT-PCR assay or a NS1 ELISA (Platelia NS1,
Biorad) test [9]. Patients with no laboratory evidence of
acute or recent dengue were assigned as OFI. For all den-
gue cases, immune status was classified based on capture
IgG results. A probable primary infection was defined by
negative IgG results on two consecutive specimens on the
acute and early phases of dengue infection, with at least
one specimen being obtained during the second week
since the onset of symptom. A probable secondary infec-
tion was defined by any positive IgG result from acute or
early samples [3, 9]. All other cases with the absence of
suitable specimens at the appropriate time points were
classified as inconclusive serology.
Laboratory evaluation
A full blood count was performed daily, while biochem-
istry tests were only performed at enrollment and then
subsequently if clinically indicated. A research sample of
EDTA plasma was stored every other day. All research
samples were processed at the different sites within 1 h
of collection, centrifuged at 500g/min for 10 min, and
then stored at − 20 °C. All the samples were transferred
on dry ice to OUCRU laboratory. CRP was measured on
these stored samples at two time points: enrollment
sample (illness day 1–3) and follow-up (day 10–21 post-
symptom onset) using the same commercial assay ac-
cording to the manufacturer’s specifications (magnetic
bead panel, cat. no. HCVD3MAG-67 K, Merck, Milli-
pore, UK) on a Luminex 200 analyzer.
Study endpoints
To compare CRP levels between dengue and OFI groups,
the outcome was laboratory-confirmed dengue or not. To
investigate the association between CRP levels and severity
in dengue patients, the primary outcome was severe or
intermediate dengue, which was defined as any of severe
Fig. 1 Study flowchart
CRP, C-reactive protein; OFI, other febrile illnesses; LOD, limit of detection
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or intermediate plasma leakage, bleeding, neurology in-
volvement, liver involvement, or other major organ failure;
all definitions were in accordance with current standard
definition for use in dengue interventional trials [10] (see
Additional file 1). Severe dengue events were rare, and the
combined endpoint of severe or intermediate dengue is
relevant for clinical practice, since less severe manifesta-
tions that require medical intervention contribute dispro-
portionately to disease burden. The decision to hospitalize
is very subjective, so we included this as a secondary out-
come. Other secondary outcomes included severe dengue
or dengue with warning signs according to WHO 2009,
and fever clearance time. Fever clearance time was defined
as the number of days from symptom onset to the day of
defervescence (for patients still febrile at hospital dis-
charge, fever clearance time was censored at the day of
discharge).
Statistical analysis
Plasma CRP levels were transformed to base-2 logarithm
(log 2) before analysis. Cox regression model was used
to investigate fever clearance time while logistic regres-
sion model was used for other outcomes. The model
comparing CRP levels between dengue and OFI groups
was adjusted for age and day of illness (DOI) at enroll-
ment. Other models for association between CRP levels
and dengue severity were adjusted for age, DOI at en-
rollment, plasma viremia levels at enrollment, and im-
mune status. Other factors, such as fluid infusion,
bacteria coinfection, antibiotic usage, and comorbidity,
had unclear potential relationship with either CRP level
and clinical outcome, and therefore, they were not con-
sidered for the adjustment. As the sample size was un-
balanced between day of illness and DOI 1 was unlikely
to have a clinical event, we decided to adjust for DOI ra-
ther than to conduct a stratification analysis on this fac-
tor. The potentially non-linear effect of CRP levels on
the outcomes was investigated using restricted cubic
splines for log 2 of CRP levels with three knots at the
10th, 50th, and 90th percentiles [11]. The effect of CRP
levels was expressed by odds ratio (OR) for the logistic
regression models and hazard ratio (HR) for the Cox re-
gression model. As the effect of CRP levels on the out-
come could differ by age, we then performed a
sensitivity analysis by subgroups of children (< 15 years
of age) and adults (≥ 15 years of age), using similar statis-
tical method as described above. Because the OFI group
included both viral and bacterial infections, this group
was further categorized into two subgroups using the
level of neutrophil counts: cases with neutrophil counts
of < 8 × 109/mL (upper limit of normal) were classified
as potential viral infection, and the others were classified
as potential bacterial infection. CRP levels between
dengue and these two subgroups were also explored
using similar model. The association between CRP in
dengue patients at enrollment and other clinical and bio-
chemical markers (platelet nadir, maximum hematocrit
(HCT) change, liver transaminases, creatinine kinase
(CK), albumin, white blood cell (WBC) count, percent-
age of neutrophils and lymphocytes) were explored using
scatter plots and Pearson’s correlation coefficients. All
analyses were performed using the statistical software R
version 3.4.4.
Results
Patient characteristics
Samples from 1120 patients with laboratory-confirmed
dengue and 400 patients with OFI were tested with CRP.
After excluding 9 samples with CRP values above the
upper range of the assay, data from 1117 patients with
laboratory-confirmed dengue and 394 patients with OFI
were included in the final analysis (Fig. 1).
Due to the selection procedure, median age, gender,
and DOI at enrollment were very similar between the
OFI and dengue group (Table 1). The age range of all
patients was 5 to 64 in the OFI group, and 5 to 73 in the
dengue group. The number of adults and children en-
rolled by site can be seen in Additional file 2. Patients
with severe dengue were younger (p < 0.001, Mann-
Whitney U test) than those with other severity grades,
and were more likely to be enrolled on day 3 (p = 0.003,
chi-squared test). In the dengue patients, the percentage
of secondary infections was highest in the severe dengue
group 33/38 (86.8%) and lowest in the uncomplicated
dengue group 542/836 (65.2%) (p < 0.001, chi-squared
test). Fewer patients with OFI were hospitalized (76/394,
19.3%, versus 421/1120, 37.6%) (p < 0.001, chi-squared
test). Within the OFI group, 131/394 (33.2%) of cases
were clinically diagnosed as bacterial infection, while in
the dengue group, there were 54/1120 (4.8%) of cases
with clinical diagnosis of bacterial coinfection (see
Additional file 3).
Laboratory characteristics
In patients with dengue infection, median CRP level at
enrollment was 30.2 mg/L, similar to the OFI group
(median CRP of 31.3) (Table 2). In comparing DOI at
enrollment, CRP level was highest in patients enrolled
on DOI 2 and lower in patients enrolled on DOI 3 or at
follow-up. This trend is similar across dengue severity
(Fig. 2). There were 30 patients in the OFI group and
896 patients in the dengue group who had CRP mea-
surements at follow-up (Table 2, Fig. 2). The follow-up
days ranged from 10 to 31 days; however, 94% follow-up
samples were within 10–20 days since onset. For the OFI
group, while the same trend was seen in patients clinic-
ally diagnosed with bacterial infection, CRP level among
patients with viral diagnosis was lower for those enrolled
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at a later time point. Considering the other laboratory
parameters, dengue patients had higher levels of liver
transaminases and CK, but lower WBC, and comparable
levels of albumin (Table 2). Dengue patients had higher
maximum HCT change, but lower PLT nadir. Among
patients with dengue, plasma viremia levels were highest
in the severe group.
Association of CRP levels and dengue diagnosis
The OFI group was separated into potential viral or
bacterial infections, using the clinical diagnosis and a
neutrophil cutoff of 8 × 109/mL. The boxplots (lower
part of Fig. 3) suggest that CRP levels in dengue pa-
tients are slightly higher than in patients with prob-
able viral infection (p = 0.003, Mann-Whitney U test)
but lower than in patients with probable bacterial in-
fection (p < 0.001, Mann-Whitney U test). These dif-
ferences resulted in a non-linear relationship between
dengue diagnosis and CRP levels, as depicted in the
upper plot in Fig. 3. CRP levels of less than 30 mg/L
(approximately the median CRP levels in dengue pa-
tients) showed that higher CRP levels associated with
higher odds of dengue diagnosis (OR for each two
times increase in CRP level was 1.28, 95% CI 1.18–
1.40). However, in patients with CRP levels ≥ 30 mg/
L, higher CRP associated with lower odds of dengue
diagnosis (OR for each two times increase in CRP
level was 0.64, 95% CI 0.55–0.73). The subgroup ana-
lysis of age < 15 and age ≥ 15 years showed similar
results (see Additional file 4). A sensitivity analysis
showed that including the 9 cases with CRP values
above the upper range of the assay did not affect the
results (ORs [95% CIs] in patients with CRP levels <
30 and ≥ 30 mg/L were 1.28 [1.18–1.40] and 0.63
[0.55–0.72], respectively).
Association of CRP level and clinical outcomes among
dengue patients
The median (IQRs) DOIs of developing the outcomes
of intermediate and severe dengue were 5 (4; 6) and
5 (5; 6), and median (IQR) times from the CRP test
to these outcomes were 3 (2; 4) and 3 (2; 4) days, re-
spectively. CRP levels at enrollment in patients with
severe or intermediate dengue were higher than in
patients with uncomplicated dengue, with median
levels (interquartile range) of 34.0 (17.4–71.8 mg/L),
Fig. 2 Summary of CRP levels by day of illness at enrollment and follow-up
The upper and lower edges of each box represent the interquartile range (25th–75th percentile) while the middle line is corresponding to the
median. The points are the actual CRP values and colored by clinical diagnosis of bacterial infection (in red), viral infection (in blue), and dengue
only infection (for patients with dengue infection) or other condition (for patients in the OFI group) (in gray). Among patients in the OFI group,
131 were clinically bacterial infection, 139 were clinically viral infection, and 124 were other conditions. The day of illness at enrollment is 1, 2, or
3, and FU is the follow-up period. The y-axis is transformed using base-2 logarithm. CRP, C-reactive protein; FU, follow-up; OFI, other
febrile illnesses
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and 28.6 mg/L (10.5–58.9 mg/L), respectively. Higher
CRP levels in the first 3 days of illness were associ-
ated with increased odds of severe or intermediate
dengue, after correcting for age, DOI at enrollment,
plasma viremia levels, and immune status (Table 3).
For each twofold increase in CRP level, the OR (95%
CI) of having severe or intermediate dengue was 1.17
(1.07–1.29). Patients with higher CRP level also had
higher odds of severe dengue with OR of 1.05 (95%
CI 0.85–1.32), but this did not reach statistical signifi-
cance. Higher CRP levels in patients with CRP ≥ 30
mg/L were strongly associated with longer fever clear-
ance time (HR 0.84, 95% CI 0.76–0.93) and
hospitalization (OR 1.37, 95% CI 1.14–1.64) (Table 3,
Fig. 4). When categorizing CRP levels into 3 groups
(< 15, 15–30, and ≥ 30 mg/L), the 2 latter groups had
significantly higher risk of severe or intermediate den-
gue compared to the lowest CRP level group (ORs
[95% CIs] were 1.66 [1.07–2.56] and 1.59 [1.10–2.32],
respectively), after correcting for age, DOI at enroll-
ment, plasma viremia, and immune status.
The subgroup analysis by age, regarding severe or
intermediate dengue, showed similar results in children
(OR 1.18, 95% CI 1.04–1.35); however, the magnitude of
effect was less in adults (OR 1.10, 95% CI 0.96–1.27)
(see Additional files 5 and 6). The strong association be-
tween higher CRP level and longer fever clearance time
and hospitalization when CRP level ≥ 30 mg/L was still
apparent in adults (HR of fever clearance was 0.78, 95%
CI 0.68–0.89; OR of hospitalization was 1.59, 95% CI
Fig. 3 Association between plasma CRP level and patients diagnosed with dengue or OFI
The log odds of having dengue (the black line) and its 95% confidence interval (the gray region) by CRP level were estimated from multivariable
logistic regression models with non-linear effect of log 2 of CRP levels, which modeled using restricted cubic splines with 3 knots, and
adjustment for age and DOI at enrollment. The red region highlights the range of CRP of 15–30 mg/L, which corresponds to the highest
probability of having dengue. The rug plots on the x-axis represent the distribution of CRP value of individual cases. Horizontal plots described
distribution of CRP levels among dengue group (in red) and OFI group (the OFI group was further separated into potential bacterial infection [in
blue] and potential viral infection [in green] based on clinical diagnosis by treating doctor [clinical diagnosis] or number of neutrophil). There are
significant differences between CRP levels in the dengue group with the potential bacterial infection group (p < 0.001) and with the potential
viral infection group (p = 0.003) (Mann-Whitney U test). The x-axis was transformed using base-2 logarithm. CRP, C-reactive protein; DOI, day of
illness; OFI, other febrile illnesses
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Table 3 Association between CRP level and clinical outcomes among dengue patients
Outcome Crude OR/HR 95% CI p value Adjusted OR/HR 95% CI p value
Severe or intermediate dengue1 1.17 1.08–1.27 < 0.001 1.18 1.07–1.30 0.001
Severe dengue1 1.04 0.87–1.25 0.710 1.05 0.85–1.32 0.638
Fever clearance time*2
CRP < 30mg/L 1.00 0.94–1.05 0.866 1.03 0.97–1.09 0.387
CRP ≥ 30 mg/L 0.89 0.81–0.97 0.010 0.84 0.76–0.92 < 0.001
Hospitalization2
CRP < 30mg/L 0.93 0.83–1.03 0.159 0.92 0.81–1.04 0.175
CRP ≥ 30 mg/L 1.28 1.08–1.51 0.004 1.36 1.13–1.63 0.001
The estimates (OR and HR) and 95% CI were reported for each one log 2 increase of CRP level, i.e., for each 2 times increase of CRP level
CI confidence interval, CRP C-reactive protein, DOI day of illness, HR hazard ratio, OR odds ratio
*We use hazard ratio (HR) to report the results of Cox model for fever clearance time outcome. All other outcomes are reported by odds ratio (OR) estimated from
logistic regression model. All adjusted estimates are derived from multivariable models adjusted for age, DOI at enrollment, plasma viremia level, and
immune status
1The models for severe or intermediate dengue and severe dengue were performed with linear effect of log 2 of CRP (the non-linear effect of log 2 of CRP was
not statistically significant: p = 0.209 for severe or intermediate dengue outcome, and p = 0.679 for severe dengue outcome)
2The models for fever clearance time and hospitalization were performed with two separated linear effect of log 2 of CRP (for CRP < 30 and CRP ≥ 30mg/L). The
non-linear effect of log 2 of CRP was statistically significant: p = 0.004 for fever clearance time outcome, and p = 0.011 for hospitalization outcome. These models
had a quadratic effect with the peak CRP level of approximately 30mg/L
Fig. 4 a–d Association between CRP level and clinical outcomes among dengue patients
The log odds (or log hazard for fever clearance time) of the outcomes (the black line) and its 95% confidence interval (the gray region) are
estimated from multivariable logistic regression models (or multivariable Cox model for fever clearance time) allowing for non-linear effect of log
2 of CRP levels using restricted cubic splines and adjusted for age, DOI at enrollment, viremia levels at enrollment, and immune status. The rug
plot on the x-axis represents the distribution of individual cases. The x-axis is transformed using base-2 logarithm. CRP, C-reactive protein
Vuong et al. BMC Medicine           (2020) 18:35 Page 9 of 13
1.25–2.04) but not in children (see Additional files 5, 7,
and 8). A sensitivity analysis including 9 cases with CRP
values above the upper range of the assay also showed
similar results (see Additional file 9).
Overall, antibiotics were used in 140/392 (35.7%) pa-
tients in the OFI group but only in 74/1118 (6.6%) pa-
tients in the dengue group. Among 428 dengue patients
with CRP level at enrollment of > 40 mg/L and without
clinically suspected bacterial infection, 417 (97%) pa-
tients did not receive antibiotics (12 from severe dengue
group, 107 from intermediate dengue group, and 298
from uncomplicated dengue group).
Association between CRP level and other laboratory tests
among dengue patients
Among dengue patients, we found positive associations
between CRP levels and total WBC count and the neu-
trophil percentage (Pearson’s correlation coefficients
were 0.25 and 0.3, respectively), and a negative associ-
ation between CRP and the lymphocyte percentage
(Pearson’s correlation coefficient was − 0.36) (Fig. 5).
There were no significant associations between CRP
level and other laboratory tests including liver transami-
nases, CK, albumin, maximum HCT change, and PLT
nadir (see Additional files 10 and 11).
Discussion
This large case-control study has shown that increased
CRP levels in the first 3 days of illness are associated
with worse dengue clinical outcomes, especially in chil-
dren. These findings provide the most robust evidence
of this relationship to date, with a consistent approach
across a large and diverse multi-national cohort ensuring
maximal generalisability. In identifying an association
between higher CRP and a modest increase in the
likelihood of progression to intermediate/severe disease,
we have demonstrated the potential utility of CRP mea-
sured early in the course of infection. This observation
could assist patient management at the point of initial
presentation, when accurate triage of those most in need
of supportive care is imperative. Existing WHO criteria
for dengue with warning signs rely heavily on clinical
examination findings, with the inclusion of changes in
hematocrit and platelet count representing the only la-
boratory markers of anticipated severity [3]. However,
while the importance of these parameters has been em-
phasized by recent studies [12–14], our findings suggest
that the approach to risk stratification could be further
refined with the inclusion of baseline CRP.
The prognostic potential of markers of generalized
inflammation has previously been suggested, in view
of the known immune-enhancing effect inherent to
dengue’s pathogenicity [4, 15]. However, recent inves-
tigation into the association between CRP and severity
of disease has yielded conflicting results [5, 6, 16–18].
Our findings are consistent with those of a smaller
study of 191 adults, which reported higher levels of
CRP during the febrile phase of illness in severe versus
non-severe dengue (defined using 2009 WHO classifica-
tion) (AUC 0.938 at a CRP threshold of 30.1 mg/L;
100% sensitivity, 76.3% specificity) [5]. Other studies
have shown a lower range of CRP in dengue infection,
but this variability is likely reflective of heterogeneity
in laboratory methods used, timing of serum sampling,
and classification of clinical outcome. Importantly, each
study reporting an absence of association between
CRP and severity of disease focused on measures of
CRP taken later than 3 days into the course of illness,
which may account for their disagreement with our
results [16, 17].
Fig. 5 Association between CRP and total white blood cell count (n = 1115), the percentages of neutrophils (n = 1110) and lymphocytes (n = 1111)
Each black point represents for each patient. The blue line is the linear regression line, and the gray region is the 95% confidence interval. Pearson’s
correlation coefficient and its 95% confidence interval are shown in the top left corner of each plot. The x-axis is transformed using base-2 logarithm.
CRP, C-reactive protein; WBC, white blood cell
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CRP is an acute-phase protein that is rapidly synthe-
sized by hepatocytes in response to inflammatory stim-
uli. It binds to a number of intrinsic and extrinsic
ligands, including many constituents of eukaryotic and
prokaryotic pathogens, enabling activation of the clas-
sical complement pathway and playing a possible role in
alternative-pathway regulation [19]. While the mechan-
ism of association between elevated CRP and dengue re-
mains unclear, immune enhancement is a known feature
of dengue pathogenesis, and it may be that severity of
disease manifestation is determined by overall magni-
tude of the immune response. The observed association
between higher CRP and increased probability of in-
creased disease severity should serve to inform future
clinical trial design, both by enriching study populations
and by encouraging exploration of potential anti-
inflammatory host-directed therapeutics.
Aside from CRP, several other components of the im-
mune response have been identified as potential prog-
nostic biomarkers [4]. Nascimento et al. found
associations between markers of dysregulation of the al-
ternative complement pathway and the development of
dengue haemorrhagic fever [16], and Juffrie et al. re-
ported levels of the proinflammatory molecules, IL-6
and sPLA2, to be predictive of dengue-associated
hypotensive shock [18]. Additional proposed prognostic
indicators include a range of proinflammatory cytokines,
markers of endothelial activation and microvascular dis-
ruption, and acute-phase proteins, but the evidence base
to support these associations is limited to small studies
with multiple possible confounding sources [4, 17, 20].
The major distinguishing feature that separates CRP
from other potential immune biomarkers, however, is its
well-established use as a clinical test, with cheap point-
of-care (POC) kits readily available across the majority
of healthcare settings. It is this ease of access, which
makes it a highly attractive option for implementation as
a prognostic tool in the resource-limited areas of great-
est dengue disease burden.
In addition to addressing the important question of
whether CRP can be prognostically useful as a dengue
biomarker, our findings add to the existing evidence
base for its use in differentiating dengue from non-
dengue causes of fever [8, 21–30]. We found the median
CRP level of approximately 30 mg/L among dengue
cases within the first 3 days of illness. Other studies
found similar levels with observed mean CRP levels of
19.0 mg/L on the first day of illness in dengue cases [23].
A number of previous studies have demonstrated the
role of CRP in differentiating dengue from specifically
bacterial [21–26] and malarial infections [25–28], al-
though the most effective CRP thresholds for predicting
underlying etiology remain difficult to define. Further-
more, the use of a CRP threshold of 20 mg/L has been
demonstrated in simulation models to be successful and
cost-effective in classifying patients into those that
would and would not benefit from antibiotics in 80% of
cases, regardless of baseline endemicity levels of different
pathogens [24]. In practice, the use of POC CRP assay
has been shown to reduce antibiotic prescribing when
implementing thresholds of significance of both 20mg/L
and 40mg/L [31]. However, our results highlight the risk
of inadvertently increasing inappropriate antibiotic pre-
scribing if dengue is not first considered in patients with
CRP > 20mg/L during seasons of high incidence. Never-
theless, growing confidence in the diagnostic value of
CRP makes POC CRP an increasingly relevant compo-
nent of antimicrobial stewardship strategy in the present
era of ever-growing antimicrobial resistance.
It is important to acknowledge some limitations of our
nested case-control study design, with observations re-
lating to the diagnostic value of CRP in dengue infection
being particularly susceptible to confounding by selec-
tion bias. For example, uncomplicated cases were chosen
to match demographic characteristics of the severe/
intermediate group, so the CRP results from these un-
complicated cases cannot be generalized to all uncompli-
cated dengue cases in the cohort. This effect would be
minimized by further exploration in future large pro-
spective cohort studies, including more patients from
Latin America. The absence of available data on alterna-
tive causes of febrile illness in the study population also
makes it difficult to draw firm conclusions about the dif-
ferentiating power of CRP.
Conclusions
Despite increasing global efforts to reduce the physical
and socioeconomic impact of dengue, reliable bio-
markers for predicting disease severity remain scarce.
This study provides important insight into the associ-
ation between higher CRP and risk of disease progres-
sion, with results that are generalisable across the range
of populations most commonly affected. These findings
can be used to influence further research design and
health policy on how best to risk-stratify patients at the
point of initial assessment.
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